Psychedelic Spotlight Interview with Daniel Carcillo

A NEW Psilocybin-Depression Study Was Just Released: The Results Are BREATHTAKING | GAME OVER?🚀🍄

Hello Psychedelic Investors! It’s an early Christmas today, as the results of a psilocybin to treat depression study were released. And the results are fantastic.
This study, which used Comp 360, Compass Pathways’ (NASDAQ: CMPS) proprietary formulation of psilocybin (the active ingredient magic mushrooms) to treat Major Depressive Disorder, had fantastic results. 50% of people improved so much that they entered remission, and another 30% improved by more than 50%.
For any followers of Psychedelic Stocks, this is amazing news, and it bodes well for Compass Pathways’ phase 2b psilocybin to treat treatment-resistant depression trials. As a reminder, this trial will be the most important event for psychedelic investors, as it is the largest ever psychedelic clinical trial. It is also the furthest advanced psilocybin clinical trial, being in phase 2b.
Even if you don’t like Compass Pathways, this is very exciting news. This will benefit the entire psychedelics industry, including companies like MindMed (MNMD), Red Light Holland (TRIP), atai Life Sciences (atai) and more.
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media!
Instagram: @psychedelicinvestor
James Twitter: @PSY_Invest
Maria’s Twitter: @PSY_Holy

Facebook: @thepsychedelicinvestor

Email: thepsychedelicinvestor@gmail.com

Music: www.bensound.com

Reference: https://psilocybinalpha.com/news/open-label-study-of-comp360-psilocybin-therapy-for-depression-in-cancer-patients-demonstrates-feasibility-of-simultaneous-psilocybin-administration-in-small-groups

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#CompassPathways #Psilocybin #Psychedelics

Hey Psychedelic Investors! There’s been so much news this week that we decided to split “This Week In Psychedelic Stocks” in 2 parts. Part Deux: ” BIG MindMed MDMA Trial, Atai’s to Compete with Tesla’s Neuralink (+Updates on CMPS, MYCO and ENBI)” might be a lot more interesting to some of you, however, I would suggest you watch Part I entitled: “HUGE Studies Released: Psychedelics About to TAKE OVER the Stock market?” That is if you are interested in the general developments in the psychedelic industry for this week.

In this episode, there’s lots of news for the psychedelic industry writ large. We’ll start up with three different studies that were released in the first week of April.

1. We’ll cover some MindMed News [ MMED / MMEDF recently announced a new MDMA study ]
2. Atai Life Sciences’ Computer Brain Interface & their clinical trial to treat Schizophrenia
3. Compass Pathways (CMPS) has amazing new price targets
4. Mydecine (MYCO / MYCOF ) has progressed four new compounds towards clinical trials
5. Entheon’s (ENBI / ENTBF) new Genetic Test Kit Updates

​…
​Timestamps:
0:00​ – Intro
1:47 – MindMed’s (MMED / MMEDF / MMQ) Announcing New Data on Personalized MDMA Dosing
6:08 – Atai Life Sciences acquires Psyber Inc to develop Brain Computer Interface -enabled digital therapeutics targeting mental health disorder
8:00 – Atai’s Subsidiary, Recognify Life Sciences, to Commence Phase 2 clinical study in Cognitive Impairment associated with Schizophrenia
9:07 – Roth Capital Upgrades Compass Pathways (CMPS) price targets & CMPS has scheduled a corporate update
10:32 – Mydecine ( MYCOF / MYCO ) Announces Four New Lead Drug Candidates for Pre-IND Meetings with the FDA & Health Canada to prepare for clinical trials. ( MYCO 001, MYCO 002, MYCO 003 & MYCO 004 )
13:02 – Entheon Biomedical (ENBI / ENTBF ) has now launched Halugen’s Psychedelics’ Genetic KIT
So that’s it for This Week in Psychedelic Stocks fellow psychedelic investors!

I hope you guys found some value in this! As our thumbnail titles states: The SHROOM BOOM is REAL! Psychedelics are taking the world by storm and psychedelic inspired companies are releasing news every single day. We’ll try to cover most of them but if there’s a company you want us to cover more in debt, please let us know in the comments and we’ll try to satisfy your demands.

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor

If you want to collaborate shoot us an email at: thepsychedelicinvestor@gmail.com

Music: www.bensound.com
https://benzinga.grsm.io/jameshallifa
​…
​
https://benzinga.grsm.io/thepsychedel

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

#MindMed​​​​ ​#MMEDStock #CMPS Stock